Li Yi, Jiao Jiakang, Qiao Haoyi, Wang Conghui, Li Linze, Jin Fengyu, Ye Danni, Chen Yawen, Zhang Qi, Li Min, Zhao Zhongpeng, Zhang Jianjun, Wang Linyuan
School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102401, China.
Pharmaceuticals (Basel). 2025 Mar 26;18(4):468. doi: 10.3390/ph18040468.
Acute lung injury (ALI) is a major cause of death in patients with various viral pneumonias. Our team previously identified four volatile compounds from aromatic Chinese medicines. Based on molecular compatibility theory, we defined their combination as aromatic molecular compatibility (AC), though its therapeutic effects and underlying mechanisms remain unclear. This study used influenza A virus (IAV) A/PR/8/34 to construct cell and mouse models of ALI to explore AC's protective effects against viral infection. The therapeutic effect of AC was verified by evaluating the antiviral efficacy in the mouse models, including improvements in their lung and colon inflammation, oxidative stress, and the suppression of the NLRP3 inflammasome. In addition, 16S rDNA and lipid metabolomics were used to analyze the potential therapeutic mechanisms of AC. Our in vitro and in vivo studies demonstrated that AC increased the survival of the IAV-infected cells and mice, inhibited influenza virus replication and the expression of proinflammatory factors in the lung tissues, and ameliorated barrier damage in the colonic tissues. In addition, AC inhibited the expression of ROS and the NLRP3 inflammasome and improved the inflammatory cell infiltration into the lung tissues. Finally, AC effectively regulated intestinal flora disorders and lipid metabolism in the model mice, significantly reduced cholesterol and triglyceride expression, and thus reduced the abnormal accumulation of lipid droplets (LDs) after IAV infection. In this study, we demonstrated that AC could treat IAV-induced ALIs through multiple pathways, including antiviral and anti-inflammatory pathways and modulation of the intestinal flora and the accumulation of LDs.
急性肺损伤(ALI)是各类病毒性肺炎患者死亡的主要原因。我们的团队之前从芳香类中药中鉴定出了四种挥发性化合物。基于分子相容性理论,我们将它们的组合定义为芳香分子配伍(AC),但其治疗效果和潜在机制仍不清楚。本研究使用甲型流感病毒(IAV)A/PR/8/34构建ALI的细胞和小鼠模型,以探究AC对病毒感染的保护作用。通过评估小鼠模型中的抗病毒功效,包括改善其肺部和结肠炎症、氧化应激以及抑制NLRP3炎性小体,验证了AC的治疗效果。此外,利用16S rDNA和脂质代谢组学分析了AC的潜在治疗机制。我们的体外和体内研究表明,AC提高了IAV感染的细胞和小鼠的存活率,抑制了流感病毒复制以及肺组织中促炎因子的表达,并改善了结肠组织的屏障损伤。此外,AC抑制了ROS和NLRP3炎性小体的表达,并改善了炎性细胞向肺组织的浸润。最后,AC有效调节了模型小鼠的肠道菌群紊乱和脂质代谢,显著降低了胆固醇和甘油三酯的表达,从而减少了IAV感染后脂滴(LDs)的异常积累。在本研究中,我们证明AC可通过多种途径治疗IAV诱导的ALI,包括抗病毒和抗炎途径以及调节肠道菌群和LDs的积累。